Methadone in Post-Herpetic Neuralgia Pain
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post-herpetic Neuralgia
Intervention: Methadone (Drug); Placebo (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: University of Sao Paulo
Summary
Neuropathic pain is a common condition and affecting 40 to 70% of the general population.
Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment.
Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose
methadone in post-herpetic neuralgia patients who remained refractory after first and second
line treatment for post-herpetic neuralgia (PHN) and had indication for the association of
an opioid agent to their current drug regimen.
Clinical Details
Official title: Methadone in Post-Herpetic Neuralgia Pain
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change in baseline Pain
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with chronic (>6 months) symptomatic PHN
- with visual analogical scale >40/100mm
- use of first and second line drugs (tricyclic antidepressants, venlafaxine and
gabapentinoids)
Exclusion Criteria:
- Don't full the criteria above
Locations and Contacts
Additional Information
Starting date: January 1998
Last updated: March 14, 2013
|
